QTTB

8.3401.65%
JP

Jodie Pope Morrison

CEO & Director

Ms. Jodie Pope Morrison was Independent Director of Verve Therapeutics, Inc. from June 2024 to July 25, 2025. Ms. Jodie Pope Morrison serves as Chief Executive Officer and Director of Q32 Bio Inc. since March 2024. Ms. Morrison previously served a member of Legacy Q32’s board of directors since September 2022. Ms. Morrison also previously served as the President and Chief Executive Officer of Legacy Q32, where she had been employed since September 2022. Prior to joining Legacy Q32, She served as Venture Partner at Atlas Venture Advisors, Inc. (formerly known as Atlas Venture L.P.). since joining on July 7, 2021. She had been the Chairman of the Board at Ribon Therapeutics, Inc. since July 2020. Ms. Morrison is an accomplished executive and Board Member with experience from start up through mid-size public biotech and pharmaceuticals. She has been Chief Executive Officer and Director at Luc Therapeutics, Inc since February 14, 2019. She served as Chief Executive Officer and President of eGenesis, Inc. from September 2017 to November 2017. Ms. Morrison strategic and operational experience in the pharmaceutical and biotech industries. From February 2019 to March 2021, she was Chief Executive Officer of Cadent Therapeutics, Inc. Ms. Morrison served as the Chief Executive Officer and President of Novus Therapeutics, Inc. from March 28, 2013 to May 2017. From December 2006 until March 2013, Ms. Morrison held other senior positions with Novus, including Chief Operating Officer, Head of Clinical Affairs and Program Operations and Vice President of Clinical Affairs and Program Operations. Since May 2017, Ms. Morrison has provided independent consulting services to venture capital, biotechnology and pharmaceutical companies. Prior to joining Novus, Ms. Morrison served as Director of Clinical Operations and Medical Affairs at Dyax Corporation or Dyax. While at Dyax, she built the clinical development team and oversaw clinical and medical operations on the hereditary angioedema and cardiothoracic surgery programs. Prior to joining Dyax, Ms. Morrison held clinical management positions at both Curis, Inc. and Diacrin, Inc. Her clinical operations experience includes programs in women's health, oncology, urology, cardiothoracic surgery, cardiac anesthesiology, allergy, immunology, neurosurgery and transplant surgery. Prior to focusing her career in clinical operations, she worked in the Cell Transplantation Laboratory at Diacrin, Inc. She served as an Independent Director of Aileron Therapeutics, Inc. from June 2017 until October 31, 2023. She was a Director of Akebia Therapeutics, Inc. since December 12, 2018 until April 03, 2020. Ms. Morrison was Interim Chief Executive Officer of Keryx Biopharmaceuticals, Inc. since April 27, 2018 until December 12, 2018. Prior to Cadent, Ms. Morrison served as Acting Chief Operating Officer at Syntimmune, Inc. (acquired by Alexion) from January 2018 to July 2018. Ms. Morrison was a Director of Keryx Biopharmaceuticals, Inc. since June 21, 2016 until December 12, 2018. She previously served on the Cadent board. She was Director of Novus Therapeutics, Inc. since March 2013. She previously served as a Director of Tokai Pharmaceuticals, Inc. since March 28, 2013. She has been recognized for her leadership skills by the Boston Business Journal’s “Power 50” and “Women to Watch” awards and WEST’s “Making a Difference” award. Ms. Jodie has dedicated herself to advocating for diversity and inclusion in the biotech industry and has served as a founding Member of the Gender Diversity Initiative at MassBio, a contributing author of a 2016 industry open letter and a leader of the CEO Forum to pivot industry efforts towards community impact. She serves as Director of Rectify Pharmaceuticals, Inc. Ms. Morrison received a B.A. in neuroscience from Mount Holyoke College, her clinical research certification from the Boston University School of Medicine and her business training through the Greater Boston Executive Program at the MIT Sloan School of Management.

Positions